Chlorpromazine versus atypical antipsychotic drugs for schizophrenia (Q24185922)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Li Bo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sai Zhao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jun Xia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Stephanie Sampson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Rashid U Zaman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 June 2020

publication date

5 April 2016

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

CD010631

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine for psychosis induced aggression or agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Cessation of medication for people with schizophrenia already stable on chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chinese classification of mental disorders (CCMD-3): towards integration in international classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Haloperidol versus chlorpromazine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine dose for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Schizophrenia: a concise overview of incidence, prevalence, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Lurasidone: an atypical antipsychotic for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

A systematic review of the prevalence of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

"The Göteborg Quality of Life Instrument"--a psychometric evaluation of assessments of symptoms and well-being among women in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Changes in daily mood and self-restraint among undercontrolled preadolescents: a time-series analysis of "acting out".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine: unlocking psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist

21 January 2018

1 reference

12 December 2020

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

1 reference

12 December 2020

Emerging role of sertindole in the management of schizophrenia.

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Measurement of quality of life: current state of the art.

1 reference

12 December 2020

[Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature]

1 reference

12 December 2020

[Artificial hibernation by pharmacodynamical and physical means.]

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1 reference

12 December 2020

Scientific fraud: action needed in China

1 reference

12 December 2020

Prognosis in schizophrenia. Prognostic predictors and outcome

1 reference

12 December 2020

Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group

1 reference

12 December 2020

Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging.

1 reference

12 December 2020

Atypical antipsychotics: new drugs, new challenges.

1 reference

12 December 2020

THE NURSES' OBSERVATION SCALE FOR INPATIENT EVALUATION: A NEW SCALE FOR MEASURING IMPROVEMENT IN CHRONIC SCHIZOPHRENIA

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

New atypical antipsychotics for schizophrenia: iloperidone

1 reference

12 December 2020

An overview of side effects caused by typical antipsychotics.

1 reference

12 December 2020

Differential olanzapine plasma concentrations by sex in a fixed-dose study

1 reference

12 December 2020

Case study: emergence of transient compulsive symptoms during treatment with clothiapine

1 reference

12 December 2020

Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list.

1 reference

12 December 2020

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010631.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD010631.PUB2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27045703%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference